Documente Academic
Documente Profesional
Documente Cultură
Treatments
Prevalence 2.2-13.8%
Quality of life
Economic Costs
Prostatitis an Important Problem!
Hypogastric Nerve
Pelvic Nerves
Pudendal Nerve
Viscus
Chronic Pain
Combination of:
- Neuroplasticity
- Central processing altered
- Trophic changes in subcutaneous tissue and muscle
All site normal sensations become painful (allodynia).
At site painful stimuli become more painful
(hyperalgesia).
Zone affected adjacent tissue (secondary hyperalgesia).
Aetiology of Chronic Prostatitis
Poorly understood
Multiple factors within and between patients
Hypotheses:
- Presence of antibiotic resistant non-culturable micro-organisms
- Chemical irritation
- Intra-ductal reflux and obstruction
- Dysfunctional high pressure voiding
- Neuropathic pain
- Pudendal nerve entrapment
- Autoimmune
Classification
Classification- NIH/EAU
Cat I Acute bacterial prostatitis
Cat II Chronic bacterial prostatitis
Cat III Prostate Pain Syndrome (CPPS)
Cat IV Asymptomatic inflammatory prostatitis
Classification- NIH/EAU
Cat I Acute bacterial prostatitis
Cat II Chronic bacterial prostatitis
Cat III Prostate Pain Syndrome (CPPS)
Discomfort or pain in the pelvic region for at least 3
months with variable voiding and sexual symptoms, no
demonstrable infection.
IIIa- inflammatory PPS- white cells in semen/eps/post
eps urine
IIIb- non-inflammatory
Cat IV
Evaluation
3 main factors:
Symptoms
WBC’s
Bacteria
Evaluation
History
Focused Examination
Condition Specific Questionnaires
Urinalysis and Culture
Semen culture
Optional: PSA, Urinary Cytology, US,
Cystoscopy, Urodynamics, Psychosocial
evaluation
Evaluation
History
Focused Examination
Condition Specific Questionnaires
Urinalysis and Culture
Semen culture
Optional: PSA, Urinary Cytology, US,
Cystoscopy, Urodynamics, Psychosocial
evaluation
Evaluation
History
Focused Examination
Condition Specific Questionnaires
Urinalysis and Culture
Semen culture
Optional: PSA, Urinary Cytology, US,
Cystoscopy, Urodynamics, Psychosocial
evaluation
Evaluation
History
Focused Examination
Condition Specific Questionnaires
Urinalysis and Culture
Semen culture
Optional: PSA, Urinary Cytology, US,
Cystoscopy, Urodynamics, Psychosocial
evaluation
Evaluation
IPSS Chronic Prostatitis Symptom Index
Evaluation
History
Focused Examination
Condition Specific Questionnaires
Urinalysis and Culture
Semen culture
Optional: PSA, Urinary Cytology, US,
Cystoscopy, Urodynamics, Psychosocial
evaluation
Evaluation
Meares-Stamey ‘4 Glass
Test’
- 1st 10-15ml of voided
urine VB1
- MSU 10-15ml urine VB2
- Prostate Massage- EPS
- 1st 10-15ml voided urine
post massage VB3
- Modified: VB1 and VB3
Evaluation
History
Focused Examination
Condition Specific Questionnaires
Urinalysis and Culture
Semen culture
Optional: PSA, Urinary Cytology, US,
Cystoscopy, Urodynamics, Psychosocial
evaluation
Evaluation
History
Focused Examination
Condition Specific Questionnaires
Urinalysis and Culture
Semen culture
Optional: PSA, Urinary Cytology, US,
Cystoscopy, Urodynamics, Psychosocial
evaluation
Evaluation
‘Diagnosis of exclusion’
Treatment- Organcentric vs.
Snowflake
Traditional Organcentric Model
Pathogenesis simple
Traditional Organcentric Model
Pathogenesis simple
Infection
‘itis’
Inflammation
PAIN!
Traditional Organcentric Model
Pathogenesis simple Antibiotics
Infection Anti-inflammatories
‘itis’ Alpha blockers
Treatment simple?
Inflammation
PAIN!
Antibiotics
Ciprofloxacin, ofloxacin, levofloxacin
~10% patients will have culturable bacteria.
J Urol. 2001 May;165(5):1539-44. Predictors of patient response to
antibiotic therapy for the chronic prostatitis/chronic pelvic pain
syndrome: a prospective multicenter clinical trial. Nickel JC et al.
However, 57% of patients on ofloxacin saw improvement
Trial 2 weeks and continue for 6 if benefit.
Alpha-blockers
Alfuzosin, Terazosin, Tamsulosin
N Engl J Med. 2008 Dec 18;359(25):2663-73. Alfuzosin and
symptoms of chronic prostatitis-chronic pelvic pain syndrome Nickel
JC et al.
Multicenter, randomized, double-blind, placebo-controlled trial of
alfuzosin.
272 men were randomly assigned to treatment for 12 weeks with
either 10 mg of alfuzosin/day or placebo.
The primary outcome was a reduction of at least 4 points in the
CPSI score.
Placebo Alfuzosin
N=134 N=138
CPSI responders 66(49%) 68(49%)
Anti-inflammatories
Celecoxib, rofecoxib
J Urol. 2003 Apr;169(4):1401-5. A randomized, placebo controlled,
multicenter study to evaluate the safety and efficacy of rofecoxib in
the treatment of chronic nonbacterial prostatitis. Nickel JC et al.
Multicenter, randomized, double-blind, placebo-controlled trial of
rofecoxib.
161 men were randomly assigned to treatment with either 25-50 mg
of rofecoxib/day or placebo.
Of the patients, 79% on 50 mg rofecoxib versus 59% on placebo
reported no or mild pain. But not statistically significant.
Neuropathic Painkillers
Amitriptylline, Pregabalin
Arch Intern Med. 2010 Sep 27;170(17):1586-93. Pregabalin for the
treatment of men with chronic prostatitis/chronic pelvic pain
syndrome: a randomized controlled trial. Pontari MA et al.
Multicenter, randomized, double-blind, placebo-controlled trial of
pregabalin.
218 men were randomly assigned to treatment for 6 weeks with
either 150-600 mg of pregabalin/day or placebo.
The primary outcome was a reduction of at least 6 points in the
CPSI score.
Placebo Pregabalin
N=106 N=218
CPSI Responders 38(36%) 103(47.2%)
So are we getting desperate?
Tenderness Psychosocial
Neurogenic/Systemic Organcentric
Infection
UPOINT
Retrospective study of 90 CPPS patients seen by
one Urologist over 12 months
Domain Percentage
Urinary 52
Psychosocial 34
Organ Specific 61
Infection 16
Neurogenic/Systemic 37
Tenderness 53
The Future: Patient-centric treatment.
‘Phenotyping’
Novel Therapies
Cernilton
Eur Urol. 2009 Sep;56(3):544-51. A pollen extract (Cernilton) in
patients with inflammatory chronic prostatitis-chronic pelvic pain
syndrome: a multicentre, randomised, prospective, double-blind,
placebo-controlled phase 3 study. Wagenlehner FM et al.
Multicentre, prospective, randomised, double-blind, placebo-
controlled trial in men with CP/CPPS (NIH IIIA)
Primary end-point, defined as a decrease of the CPSI total score by
at least 25% or at least 6 points.
Placebo Cernilton
N=69 N=70
CPSI Responders 50% 71%
Take Home Points
Poorly understood aetiology/pathogenesis.
Heterogenous disease.
Established treatments perform poorly in RCT’s.
Phenotyping patient and treatment.